Table 1

Summary of test characteristics of the most commonly used assays in the UK for RAS testing of colorectal carcinoma to guide anti-EGFR therapy

Pyrosequencing5%CostCertain mutations (eg, c.35G>T) are less easily detected
COBAS* 5%Speed, automated analysisLimited mutation range
Therascreen RGQ PCR†1–5%SpeedLimited mutation range
Sanger sequencing10–20%Wide mutation rangeLabour intensive, time consuming
HRM analysis1–5%Cost, speedUnable to distinguish between mutation types
  • *Roche Diagnostics Ltd, Burgess Hill, UK.

  • †Qiagen Ltd, Manchester, UK.